Conferences

Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, addressed by 300+ Speakers from EMA, European Commission, FDA and other national regulatory agencies. Most popular sessions included Implementation of the New Pharmacovigilance Legislation, the Regulatory Town Hall Meeting and the sell-out European Landscape on HTA - the EUnetHTA Joint Action. Eighteen pre-conference tutorials were led by an expert faculty and 120 students, young professional and patients all attended sessions created especially for them.

Attendees will gain knowledge and hear how their peers are staying relevant in a market with razor thin margins and increasing competition for fewer products. The 6th Product and Pipeline Enhancement for Generics Conference, 23–25 July 2013 in Washington DC, USA, will aid organizations in diversifying their product, while dealing with the pressures of the patent cliff.

IBC’s 5th Annual BioProcess International China Conference provides you with practical tools, techniques and strategies to improve your upstream and downstream development efforts and offer you insights into state-of-the-art approaches for GMP manufacturing and scale-up that meet international standards.

DIA Europe’s 2012 Clinical Forum in October this year promises to be an important multidisciplinary conference for all engaged in the clinical development and therapeutic use of medicines. The theme for 2012 is ‘The Empowered Patient’, an acknowledgement of the inescapable fact that the evolution of technology and electronic communication has given patients the ability to find and share health information which will impact their treatment choices – empowering them to become more engaged in their care and to participate in decisions about it.

There is now a crucial need for a framework that allows global biosimilars development.

At the 10^th International Symposium on Biosimilar Medicines, organised by the European Generics medicines Association, held in London, UK, on 19–20 April 2012; the European Commission (EC) highlighted the need to stimulate wider use of generic medicines.

At the 2012 Biosimilars Medicines: 10^th EGA International Symposium, held in London, UK, on 19–20 April 2012; Mr Nils Behrndt (Deputy Head of Cabinet DG Sanco, European Commission) announced that the European Commission (EC) wishes to stimulate the global development of biosimilars. The EC has thereby two objectives:

Opportunities for increased employment and growth in the generic and biosimilar medicines markets should be exploited in order to avoid Europe falling behind other regions according to the European Generic medicines Association (EGA).

At its 9th International Symposium on Biosimilar Medicines held in London, UK, on 14-15 April 2011 the European Generic medicines Association (EGA) highlighted the need for an EU industrial policy to enhance the competitiveness of biosimilars.

Cyclobenzaprine is a muscle relaxant, structurally related to first-generation tricyclic antidepressants. At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Ms Tatiane Maria de Lima Souza Brioschi et al. of the University of Sao Paolo in Brazil presented a poster entitled ‘Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets’ in which the bioequivalence of two brands of cyclobenzaprine 10 mg tablets in healthy volunteers was evaluated.